maralixibat · Livmarli

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Alagille Syndrome

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
US
  • Cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC)
Product first approved 2021Outside this platform's coverageFDA label
JP
  • Pruritus associated with cholestasis in Alagille syndrome (and PFIC)
Product first approved 2025takeda.com
CN
  • Cholestatic pruritus in Alagille syndrome patients aged 1 year and older (CAN108, CANbridge)
Product first approved 2023biospace.com
EU
  • Cholestatic pruritus in patients with Alagille syndrome 2 months of age and older (marketing authorisation under exceptional circumstances); PFIC added
Product first approved 2022EMA

Company guidance: regulatory filing expected first half of 2027 (Mirum Pharmaceuticals, Inc., 3 Nov 2026). “We plan to submit a supplemental New Drug Application (“sNDA”) for Livmarli based on the EXPAND study in the first half of 2027.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Other / comorbidity
NCT06553768 · Mirum Pharmaceuticals, Inc.
2024-10-14 – 2026-12 · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
What this study did
NCT04185363 · Mirum Pharmaceuticals, Inc.
2020-01-08 – 2025-04-23 · Progressive Familial Intrahepatic Cholestasis (PFIC)
What this study did
NCT03905330 · Mirum Pharmaceuticals, Inc.
2019-07-09 – 2022-09-01 · Progressive Familial Intrahepatic Cholestasis (PFIC)
What this study did
NCT03353454 · Mirum Pharmaceuticals, Inc.
2018-10-25 – 2020-06-15 · Progressive Familial Intrahepatic Cholestasis (PFIC)
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT06413368 · Children's Hospital Los Angeles
2025-04-09 – 2027-06-30 · Constipation Chronic Idiopathic, Cystic Fibrosis
What this study did
Phase 2 (9)
Alagille Syndrome
NCT04729751 · Mirum Pharmaceuticals, Inc.
2021-09-09 – 2024-12-17 · Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease
What this study did
NCT02047318 · Mirum Pharmaceuticals, Inc.
2013-12-20 – 2020-06-17 · Alagille Syndrome
What this study did
Other / comorbidity
NCT07823127 · Mirum Pharmaceuticals, Inc.
2027-01-15 – 2029-01-12 · Intrahepatic Cholestasis of Pregnancy
What this study did
NCT07389031 · Imperial College London
2026-04-01 – 2028-03-31 · Intrahepatic Cholestasis of Pregnancy
What this study did
NCT04168385 · Mirum Pharmaceuticals, Inc.
2020-01-16 – 2024-09-04 · Cholestatic Liver Disease
What this study did
NCT04524390 · Mirum Pharmaceuticals, Inc.
2021-07-08 – 2024-02-07 · Biliary Atresia
What this study did
NCT02057718 · Mirum Pharmaceuticals, Inc.
2014-03-01 – 2020-05-08 · Progressive Familial Intrahepatic Cholestasis (PFIC)
What this study did
Phase 1 (1)
Other / comorbidity
NCT02475317 · Mirum Pharmaceuticals, Inc.
2015-06-01 – 2015-12-01 · Healthy Volunteers
What this study did
Phase 4 (1)
Alagille Syndrome
NCT07290257 · Mirum Pharmaceuticals, Inc.
2025-09-25 – 2030-12-22 · Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
What this study did

Competitive landscape

Other Ileal bile acid transporter (IBAT) drugs

volixibat. Compare all 2 Ileal bile acid transporter (IBAT) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Maralixibat (Livmarli): this drugApprovedSmall moleculeIleal bile acid transporter (IBAT)Partial signal
NCT04185363: Mean Change From Baseline Over Time in the Average Morning ItchRO(Obs) Severity Score (From Baseline to Weeks 75-78): The Primary Cohort -1.633 score on a scale (Standard Deviation 1.4416) | PFIC Cohort -1.602 score on a scale (Standard Deviation 1.3649)
NCT03905330: Mean Change in the Average Morning ItchRO(Obs) Severity Score in the Primary Cohort (MMRM model was used with inputs of the average changes from baseline (BL) to Weeks 1-6, 7-10, 11-14, 15-18, 19-22, 23-26, and other covariates. The average change from BL over Weeks 15-26 is calculated in the model and presented as a single number.): Primary Cohort Maralixibat -1.718 Score on a scale (95% CI -2.272 to -1.163) | Primary Cohort Placebo -0.628 Score on a scale (95% CI -1.136 to -0.121)
Volixibat
Phase 2(overall)
Small moleculeIleal bile acid transporter (IBAT)not yet gradedNo reviewed efficacy summary

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Livmarli (maralixibat) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Phase 2/3Constipation Chronic Idiopathic, Cystic FibrosisRecruiting
Est. primary completion 2027-06-30 · NCT06413368 · CT.gov ↗
What to watch
2028 (1)
March 2028 (1)
Phase 2Intrahepatic Cholestasis of PregnancyNot yet recruiting
Est. primary completion 2028-03-31 · NCT07389031 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 2Intrahepatic Cholestasis of PregnancyNot yet recruiting
Est. primary completion 2029-01-12 · NCT07823127 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
Phase 4Alagille SyndromeRecruiting
Est. primary completion 2030-09-22 · NCT07290257 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 October 2026Topline resultEXPAND Phase 3 topline: primary endpoint met
Mirum Pharmaceuticals, Inc. · Source ↗
December 2023Topline resultPhase 2b EMBARK in biliary atresia did not meet its primary or key secondary endpoints